| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GLP1 |
| Uniprot No | P01275 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 53-89aa |
| 氨基酸序列 | HSQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIA |
| 预测分子量 | 30 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是模拟生成的3篇关于GLP-1重组蛋白的参考文献示例(非真实文献，仅作格式参考)：
1. **《重组人GLP-1类似物的设计及降糖活性研究》**
作者：张伟等
摘要：本研究通过基因工程技术对GLP-1分子进行结构修饰，设计出长效重组GLP-1类似物，并在糖尿病小鼠模型中验证其显著降低血糖水平的效果，半衰期延长至12小时以上。
2. **《GLP-1受体激动剂对肥胖相关代谢综合征的作用机制》**
作者：Johnson M, et al.
摘要：通过细胞实验和临床试验，证明重组GLP-1蛋白可通过激活下丘脑受体抑制食欲，同时改善胰岛素敏感性，有效缓解肥胖患者的代谢异常。
3. **《新型GLP-1/FGF21双靶点融合蛋白的构建与药效评价》**
作者：Chen L, et al.
摘要：利用重组蛋白技术将GLP-1与FGF21结合，开发出双功能分子，在动物模型中显示协同降糖和减脂作用，为糖尿病合并脂肪肝治疗提供新策略。
(注：如需真实文献，建议通过PubMed、Google Scholar等平台检索关键词如"recombinant GLP-1 protein"、"GLP-1 receptor agonist development"。)
Glucagon-like peptide-1 (GLP-1) is an incretin hormone primarily secreted by intestinal L-cells in response to nutrient intake. Discovered in the 1980s, it plays a critical role in glucose homeostasis by stimulating insulin secretion, inhibiting glucagon release, slowing gastric emptying, and promoting satiety. However, native GLP-1 has a very short half-life (<2 minutes) due to rapid degradation by dipeptidyl peptidase-4 (DPP-4) and renal clearance, limiting its therapeutic potential.
This limitation drove the development of GLP-1 receptor agonists (GLP-1 RAs) through recombinant protein engineering. Early innovations included exenatide, derived from the exendin-4 peptide found in Gila monster saliva, which shares 53% homology with human GLP-1 but resists DPP-4 degradation. Subsequent generations focused on structural modifications to enhance stability and prolong action. Liraglutide, introduced in 2010. incorporated a fatty acid side chain for albumin binding, extending its half-life to 13 hours. Semaglutide, approved in 2017. achieved once-weekly dosing through additional structural optimization and albumin conjugation.
These recombinant analogs not only improve glycemic control in type 2 diabetes but also demonstrate cardiovascular benefits and significant weight-loss effects via central nervous system pathways. Their success has expanded research into dual/triple agonists targeting GLP-1. GIP, and glucagon receptors for enhanced metabolic outcomes. Recent advancements in delivery systems, including oral formulations and sustained-release technologies, further address patient compliance challenges. Beyond diabetes and obesity, ongoing studies explore potential applications in non-alcoholic steatohepatitis (NASH), neurodegenerative diseases, and cardiorenal protection, positioning GLP-1-based therapies as transformative agents in metabolic medicine.
×
